ReviewMetabolic syndrome and related disorders2009
Metabolic syndrome and cancer.
Review in Metabolic syndrome and related disorders, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 4 syntheses or guidelines pooled it, 188 citations in OpenAlex.
- Association Between Metabolic Syndrome and Risk of Laryngeal Cancer: A Systematic Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- A Meta-Analysis of Microbial Therapy Against Metabolic Syndrome: Evidence From Randomized Controlled Trials.Frontiers in nutrition · 2021Pooled it
- The Role of Obesity, Type 2 Diabetes, and Metabolic Factors in Pancreatic Cancer: A Mendelian Randomization Study.Journal of the National Cancer Institute · 2017Pooled it
- The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence.Journal of experimental & clinical cancer research : CR · 2013Pooled it
- Article
- Machine learning-predicted insulin resistance is a risk factor for 12 types of cancer.Nature communications · 2026Article
- Association between the psoas muscle index and disease progression and mortality in testicular germ cell tumours.The Indian journal of medical research · 2026Article
- Impact of metabolically healthy and metabolically unhealthy obesity on cardiac arrest and mortality in pulmonary embolism hospitalizations in elderly patients with cancer.Lung India : official organ of Indian Chest Society · 2026Article
- Amino acid metabolism-related LncRNAs as prognostic biomarkers and predictors of immunotherapy response in hepatocellular carcinoma.Discover oncology · 2025Article
- Cross-tissue coordination between SLC nucleoside transporters regulates reproduction in Caenorhabditis elegans.PLoS genetics · 2025Article
- Therapeutic Potential of Anti-Diabetes Drugs and Anti-Dyslipidemia Drugs to Mitigate Head and Neck Cancer Risk in Metabolic Syndrome.CNS neuroscience & therapeutics · 2025Review
- Obesity, Metabolic Syndrome, and Sugar-Sweetened Beverages (SSBs) in America: A Novel Bioethical Argument for a Radical Public Health Proposal.Journal of bioethical inquiry · 2025Article
- Assessing gastric cancer risk through longitudinal health check-up data: Insights from a national cohort study in South Korea.PloS one · 2025Article
- Metabolic syndrome: risk factors and molecular drug targets.EXCLI journal · 2025Review
- Thrombo-inflammation linking androgen suppression with cardiovascular risk in patients with prostate cancer.Cardio-oncology (London, England) · 2024Review
- Synthesis and Evaluation of Thiazolyl-indole-2-carboxamide Derivatives as Potent Multitarget Anticancer Agents.ACS omega · 2024Article
- The Interlinking Metabolic Association between Type 2 Diabetes Mellitus and Cancer: Molecular Mechanisms and Therapeutic Insights.Diagnostics (Basel, Switzerland) · 2024Review
- Impact of obesity on in-hospital mortality and morbidity among patients admitted for antineoplastic chemotherapy: a nationwide analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Effects of T2DM on cancer progression: pivotal precipitating factors and underlying mechanisms.Frontiers in endocrinology · 2024Review
- The impact of cellular environment onFuture science OA · 2023Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Since its first description by Reavan in 1988, accepted criteria for clinical identification of the components of metabolic syndrome have been promulgated by the National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATP III) and the World Health Organization (WHO) as well as the International Diabetes Federation (IDF), and the American Association of Clinical Endocrinologists (AACE). Insulin resistance is a common metabolic abnormality underlying type 2 diabetes mellitus and is also an independent risk factor for cardiovascular disease. Although ATP III identified cardiovascular disease (CVD) as the primary clinical outcome of the metabolic syndrome, we now have evidence that metabolic syndrome is associated with type 2 diabetes mellitus, polycystic ovarian disease, nonalcoholic fatty liver disease, and possibly some cancers. This review summarizes evidence in support of the relationship between metabolic syndrome and various cancers and possible underlying mechanisms and therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.